Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings.

Francesco Giambanco, Silvio Fasullo, Salvatore Paterna, Giorgio Marenghini, Filippo Ganci, Giovanni Polizzi, Giuseppe Vitale, Sebastiano Scalzo, Sergio Cannizzaro, Francesco Giambanco, Pietro Di Pasquale, Sergio Fasullo, Stefania Cannizzaro

    Risultato della ricerca: Article

    8 Citazioni (Scopus)

    Abstract

    The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group 1 (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), troponin I, creatine kinase and brain natriuretic peptide plasma levels], ECG and echocardiogram were performed at baseline and daily up to discharge. All of the patients were followed as outpatients for 3 months to evaluate any recurrence of pericarditis. The two groups were similar in age, sex and laboratory parameters [group 1 (the statin group), n=28 patients; gender, 18 male and ten female; and age, 29.5±5.7 years; group 2 (placebo group), n=27 patients; gender, 16 male/11 female; and age, 29.2±4.8 years]. The statin group, when compared with the placebo group, had a significantly faster reduction in CRP values (5.0±1.0 compared with 6.0±2.0 days respectively; P=0.022), ST segment normalization (3.5±1.0 compared with 4.5±1.0 days respectively; P=0.001), pericardial effusion (4.5±1.0 compared with 5.5±1.0 days respectively; P=0.001) and ESR (5.0±1 compared with 6.0±2 days respectively; P=0.022). Our results show that the combination of statin and indomethacin treatment in patients with acute pericarditis is feasible, with a significant reduction in inflammatory markers and a favourable trend in hospitalization time (5.5±2.0 compared with 6.5±2.0 days respectively; P=0.069). However, these preliminary findings require further studies in a larger sample of patients
    Lingua originaleEnglish
    pagine (da-a)443-448
    Numero di pagine6
    RivistaClinical Science
    Volume113
    Stato di pubblicazionePublished - 2007

    Fingerprint

    Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Pericarditis
    Indomethacin
    Placebos
    Blood Sedimentation
    C-Reactive Protein
    Troponin I
    Pericardial Effusion
    Brain Natriuretic Peptide
    Creatine Kinase
    Electrocardiography
    Hospitalization
    Outpatients
    Cell Count
    Inflammation
    Safety
    Recurrence
    Therapeutics

    All Science Journal Classification (ASJC) codes

    • Medicine(all)

    Cita questo

    Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings. / Giambanco, Francesco; Fasullo, Silvio; Paterna, Salvatore; Marenghini, Giorgio; Ganci, Filippo; Polizzi, Giovanni; Vitale, Giuseppe; Scalzo, Sebastiano; Cannizzaro, Sergio; Giambanco, Francesco; Di Pasquale, Pietro; Fasullo, Sergio; Cannizzaro, Stefania.

    In: Clinical Science, Vol. 113, 2007, pag. 443-448.

    Risultato della ricerca: Article

    Giambanco, F, Fasullo, S, Paterna, S, Marenghini, G, Ganci, F, Polizzi, G, Vitale, G, Scalzo, S, Cannizzaro, S, Giambanco, F, Di Pasquale, P, Fasullo, S & Cannizzaro, S 2007, 'Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings.', Clinical Science, vol. 113, pagg. 443-448.
    Giambanco, Francesco ; Fasullo, Silvio ; Paterna, Salvatore ; Marenghini, Giorgio ; Ganci, Filippo ; Polizzi, Giovanni ; Vitale, Giuseppe ; Scalzo, Sebastiano ; Cannizzaro, Sergio ; Giambanco, Francesco ; Di Pasquale, Pietro ; Fasullo, Sergio ; Cannizzaro, Stefania. / Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings. In: Clinical Science. 2007 ; Vol. 113. pagg. 443-448.
    @article{fe37830402454aa0a06becce115c87e1,
    title = "Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings.",
    abstract = "The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group 1 (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), troponin I, creatine kinase and brain natriuretic peptide plasma levels], ECG and echocardiogram were performed at baseline and daily up to discharge. All of the patients were followed as outpatients for 3 months to evaluate any recurrence of pericarditis. The two groups were similar in age, sex and laboratory parameters [group 1 (the statin group), n=28 patients; gender, 18 male and ten female; and age, 29.5±5.7 years; group 2 (placebo group), n=27 patients; gender, 16 male/11 female; and age, 29.2±4.8 years]. The statin group, when compared with the placebo group, had a significantly faster reduction in CRP values (5.0±1.0 compared with 6.0±2.0 days respectively; P=0.022), ST segment normalization (3.5±1.0 compared with 4.5±1.0 days respectively; P=0.001), pericardial effusion (4.5±1.0 compared with 5.5±1.0 days respectively; P=0.001) and ESR (5.0±1 compared with 6.0±2 days respectively; P=0.022). Our results show that the combination of statin and indomethacin treatment in patients with acute pericarditis is feasible, with a significant reduction in inflammatory markers and a favourable trend in hospitalization time (5.5±2.0 compared with 6.5±2.0 days respectively; P=0.069). However, these preliminary findings require further studies in a larger sample of patients",
    author = "Francesco Giambanco and Silvio Fasullo and Salvatore Paterna and Giorgio Marenghini and Filippo Ganci and Giovanni Polizzi and Giuseppe Vitale and Sebastiano Scalzo and Sergio Cannizzaro and Francesco Giambanco and {Di Pasquale}, Pietro and Sergio Fasullo and Stefania Cannizzaro",
    year = "2007",
    language = "English",
    volume = "113",
    pages = "443--448",
    journal = "Clinical Science",
    issn = "0143-5221",
    publisher = "Portland Press Ltd.",

    }

    TY - JOUR

    T1 - Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings.

    AU - Giambanco, Francesco

    AU - Fasullo, Silvio

    AU - Paterna, Salvatore

    AU - Marenghini, Giorgio

    AU - Ganci, Filippo

    AU - Polizzi, Giovanni

    AU - Vitale, Giuseppe

    AU - Scalzo, Sebastiano

    AU - Cannizzaro, Sergio

    AU - Giambanco, Francesco

    AU - Di Pasquale, Pietro

    AU - Fasullo, Sergio

    AU - Cannizzaro, Stefania

    PY - 2007

    Y1 - 2007

    N2 - The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group 1 (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), troponin I, creatine kinase and brain natriuretic peptide plasma levels], ECG and echocardiogram were performed at baseline and daily up to discharge. All of the patients were followed as outpatients for 3 months to evaluate any recurrence of pericarditis. The two groups were similar in age, sex and laboratory parameters [group 1 (the statin group), n=28 patients; gender, 18 male and ten female; and age, 29.5±5.7 years; group 2 (placebo group), n=27 patients; gender, 16 male/11 female; and age, 29.2±4.8 years]. The statin group, when compared with the placebo group, had a significantly faster reduction in CRP values (5.0±1.0 compared with 6.0±2.0 days respectively; P=0.022), ST segment normalization (3.5±1.0 compared with 4.5±1.0 days respectively; P=0.001), pericardial effusion (4.5±1.0 compared with 5.5±1.0 days respectively; P=0.001) and ESR (5.0±1 compared with 6.0±2 days respectively; P=0.022). Our results show that the combination of statin and indomethacin treatment in patients with acute pericarditis is feasible, with a significant reduction in inflammatory markers and a favourable trend in hospitalization time (5.5±2.0 compared with 6.5±2.0 days respectively; P=0.069). However, these preliminary findings require further studies in a larger sample of patients

    AB - The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group 1 (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), troponin I, creatine kinase and brain natriuretic peptide plasma levels], ECG and echocardiogram were performed at baseline and daily up to discharge. All of the patients were followed as outpatients for 3 months to evaluate any recurrence of pericarditis. The two groups were similar in age, sex and laboratory parameters [group 1 (the statin group), n=28 patients; gender, 18 male and ten female; and age, 29.5±5.7 years; group 2 (placebo group), n=27 patients; gender, 16 male/11 female; and age, 29.2±4.8 years]. The statin group, when compared with the placebo group, had a significantly faster reduction in CRP values (5.0±1.0 compared with 6.0±2.0 days respectively; P=0.022), ST segment normalization (3.5±1.0 compared with 4.5±1.0 days respectively; P=0.001), pericardial effusion (4.5±1.0 compared with 5.5±1.0 days respectively; P=0.001) and ESR (5.0±1 compared with 6.0±2 days respectively; P=0.022). Our results show that the combination of statin and indomethacin treatment in patients with acute pericarditis is feasible, with a significant reduction in inflammatory markers and a favourable trend in hospitalization time (5.5±2.0 compared with 6.5±2.0 days respectively; P=0.069). However, these preliminary findings require further studies in a larger sample of patients

    UR - http://hdl.handle.net/10447/23435

    M3 - Article

    VL - 113

    SP - 443

    EP - 448

    JO - Clinical Science

    JF - Clinical Science

    SN - 0143-5221

    ER -